TCT TAVR and TMTT Investor Q&A - EDWARDS LIFESCIENCES CORP

Financial Performance:

• The transcript does not disclose specific financial figures (revenue, earnings, cash flow, debt, or margins) for Edwards Lifesciences, as the session focused exclusively on clinical trial results.
• Management highlighted the company's long-term financial commitment to R&D, citing "years of investment" and a "sizable investment" in the TMTT and TAVR portfolios to support innovation and evidence generation.
• A referenced cost-effectiveness study (NEUTAL trial on early TAVR) indicated that early intervention falls within the "strongly cost-effective range" compared to other CMS-reimbursed therapies, suggesting favorable long-term economic value.

Guidance and Future Outlook:

• Immediate Action: Physicians are encouraged to begin advanced screening and referral of moderate aortic stenosis (AS) patients to valve clinics immediately, rather than waiting for formal FDA or CMS indication changes.
• Regulatory Timeline: Management expects the FDA to potentially grant a Class II recommendation (likely transitioning to Class I) for TAVR in moderate AS with at-risk features within "several years," anticipating corroborative studies to support the single-trial data.
• Market Expansion: Anticipated significant growth in TAVR volume as the "moderate AS" population is recognized as a large, underserved market, with projections that 30-50% of referred moderate AS patients may actually have misclassified severe disease.
• Long-term Goals: Aiming to redefine aortic stenosis treatment from a categorical model (mild/moderate/severe) to a continuum of "clinically significant" disease, shifting the treatment trigger to earlier in the disease spectrum.

Business Segments and Product Lines:

• TMTT (Mitral and Tricuspid Transcatheter Therapies):
  • Pascal System (CLASP2-TR): Met primary six-month endpoint; demonstrated superior clinical benefit (Win Ratio 1.98) compared to optimal medical therapy, driven primarily by patient-reported quality of life (KCCQ) improvements (57% vs. 25%).
  • TRIC-HF: Presented data showing a mortality benefit and reduction in heart failure hospitalizations by enriching the patient population with specific cardiorenal/hepatorenal risk factors.
  • Portfolio: Established a full portfolio of repair (Pascal) and replacement options for both mitral and tricuspid valves.
• TAVR:
  • SAPIEN 3 Platform: PROGRESS trial data confirmed the safety and efficacy of the SAPIEN 3 valve in patients with moderate AS and at-risk features.
  • Activation/Screening: Real-world data (ACTIVATE study of 15M patients) revealed that 65% of aortic stenosis cases are moderate, with 80% of these patients possessing at least one at-risk feature, identifying a massive untapped market.

Market and Competitive Landscape:

• Paradigm Shift: The PROGRESS trial challenges the historical "watch and wait" surveillance model, positioning Edwards as the catalyst for changing clinical practice regarding moderate AS.
• Underdiagnosis: Significant opportunity exists due to the underdiagnosis and misclassification of tricuspid regurgitation and aortic stenosis in general cardiology practices.
• Competition: Management emphasized that while other devices exist, Edwards' unique full portfolio of repair and replacement options in TMTT provides a strategic advantage.
• Physician Behavior: Anticipated "freak out" response from physicians upon publication, leading to rapid referrals to specialized valve clinics for comprehensive evaluation (CT scan, detailed echo).

Risks and Challenges:

• Diagnostic Gaps: Risk of continued under-treatment due to the indolent nature of symptoms and the difficulty in distinguishing moderate vs. severe disease without advanced imaging.
• Guideline Lag: Current guidelines rely on categorical definitions that the trial data suggests are artificial and anachronistic, potentially slowing widespread adoption until guidelines are updated.
• Reimbursement Uncertainty: While CMS language has been updated to allow "reasonable and necessary" applications, formal NCD (National Coverage Determination) updates for moderate AS indication are pending formal FDA approval.
• Clinical Heterogeneity: Moderate AS is a heterogeneous population; not all patients have at-risk features, requiring careful patient selection to avoid overtreatment.

Management Commentary and Tone:

• Tone: Highly confident, visionary, and passionate. Management framed the results as a "revolution" and a "turning point" in structural heart disease.
• Confidence: Expressed strong belief in the safety profile (0% mortality, 0% disabling stroke at 30 days in PROGRESS) and the clinical necessity of early intervention.
• Patient-Centric: Emphasized that patients prioritize feeling better and avoiding heart failure hospitalizations over waiting for mortality data in a trial setting.
• Critique of Status Quo: Management explicitly criticized the "passive surveillance" paradigm and editorial comments suggesting moderate AS is benign, labeling them "ill-advised" and based on outdated data.

Analyst Questions and Answers:

• Mortality Benefit: Analysts questioned the lack of statistically significant mortality difference in PROGRESS at two years. Management explained the trial was not powered for mortality, the control arm received high-quality surveillance (unlike real-world), and mortality benefits in similar trials (Early TAVR) typically emerge after 3+ years.
• Indication vs. Reality: Analysts asked about the disconnect between the "niche" conclusion of an editorial and the data. Management rebutted this, citing the ACTIVATE real-world data showing 80% of moderate AS patients have at-risk features, making it a large market, not a niche.
• Adoption Timeline: Questions on reimbursement and adoption timelines. Management suggested that while formal label expansion takes time, clinical uptake will begin immediately as physicians recognize the data and the limitations of current guidelines.
• Repair vs. Replace: In the tricuspid space, management noted a preference for repair when anatomy allows, but replacement is often necessary when a "good result" (≤ mild TR) cannot be achieved with repair alone.

Other Key Points:

• Trial Evolution: The CLASP2-TR trial endpoint evolved from 2 years to 6 months due to device approvals (Evoque, TriClip) causing attrition in the control group.
• Risk Stratification: The PROGRESS trial utilized 7 specific "at-risk features" (symptoms, diastolic dysfunction, calcium score, LVEF drop, NT-proBNP, AFib, STS-PROM) to select patients, proving these are easily obtainable metrics.
• Quality of Life: Both CLASP2-TR and PROGRESS showed immediate and sustained improvements in patient-reported health outcomes (KCCQ), with PROGRESS patients avoiding a 10-20 point decline in scores seen in the surveillance group.
• Safety Benchmark: The 0% mortality and 0% disabling stroke rates at 30 days in moderate AS patients were highlighted as unprecedented, comparable to "less risky" procedures like colonoscopy.
• Future Research: Management confirmed ongoing work on additional studies to corroborate PROGRESS results and further refine the "clinically significant" definition of aortic stenosis.